TELA Bio Announces Inducement Grants for Newly-Hired Employees Under Nasdaq Rule

TELA Bio

MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company, has recently announced the approval of inducement grants by its Compensation Committee. The grants, which cover 40,700 shares of its common stock, were issued to thirty-one newly-hired employees on November 6, 2023.

The inducement grants were issued under the Nasdaq Rule 5635(c)(4) as part of each individual’s employment compensation package. Notably, these grants are considered an essential factor in the acceptance of employment with TELA Bio by these individuals.

The granted restricted stock units will vest over a period of four years in equal annual installments. The vesting is contingent upon each individual’s continued service with TELA Bio through the applicable vesting dates. This approach aligns the interests of the employees with those of the shareholders and the long-term success of the company.

TELA Bio, a leading player in the medical technology industry, is renowned for its innovative technologies that prioritize patient outcomes. The company’s focus is on the preservation and restoration of the patient’s own anatomy, providing advanced, cost-effective solutions for soft-tissue reconstruction. These solutions leverage the patient’s natural healing response while minimizing their long-term exposure to permanent synthetic materials.

These inducement grants follow the company’s commitment to attracting and retaining the best talent in the industry. By offering competitive compensation packages, TELA Bio ensures it has the team required to continue advancing its mission of providing innovative medical technologies to surgeons and patients alike.

Investors and stakeholders in TELA Bio can expect the company to continue leveraging such strategies to drive its growth and innovation in the healthcare sector. As the firm continues to pioneer in its field, the inducement grants are a clear sign of its commitment to investing in people as a key asset for the company’s future success.

READ:  Ocugen to Present Pioneering Gene Therapy Data at Retinal Innovation Summit

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.